- Home
- Publications
- Publication Search
- Publication Details
Title
Use of adjuvants for immunotherapy
Authors
Keywords
-
Journal
Human Vaccines & Immunotherapeutics
Volume 13, Issue 8, Pages 1774-1777
Publisher
Informa UK Limited
Online
2017-06-12
DOI
10.1080/21645515.2017.1321725
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Immunological effects of a novel RNA-based adjuvant in liver cancer patients
- (2016) Luisa Circelli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile
- (2015) Regina Heidenreich et al. INTERNATIONAL JOURNAL OF CANCER
- Defined TLR3-specific adjuvant that induces NK and CTL activation without significant cytokine production in vivo
- (2015) Misako Matsumoto et al. Nature Communications
- TLR-3 stimulation improves anti-tumor immunity elicited by dendritic cell exosome-based vaccines in a murine model of melanoma
- (2015) Martina Damo et al. Scientific Reports
- Trial Watch: Peptide-based anticancer vaccines
- (2015) Jonathan Pol et al. OncoImmunology
- Synergistic Anticancer Effects of Pam3CSK4 and Ara-C on B-Cell Lymphoma Cells
- (2014) S.-K. Lee et al. CLINICAL CANCER RESEARCH
- Dual Signaling of MyD88 and TRIF Is Critical for Maximal TLR4-Induced Dendritic Cell Maturation
- (2014) H. Shen et al. JOURNAL OF IMMUNOLOGY
- Key roles of adjuvants in modern vaccines
- (2013) Steven G Reed et al. NATURE MEDICINE
- Cancer Immunotherapy
- (2013) J. Couzin-Frankel SCIENCE
- Pattern recognition receptors: sentinels in innate immunity and targets of new vaccine adjuvants
- (2012) Colleen Olive Expert Review of Vaccines
- New adjuvants aim to give whooping cough vaccine a boost
- (2012) Melinda Wenner Moyer NATURE MEDICINE
- Trial watch
- (2012) Erika Vacchelli et al. OncoImmunology
- PROVENGE (Sipuleucel-T) in Prostate Cancer: The First FDA-Approved Therapeutic Cancer Vaccine
- (2011) M. A. Cheever et al. CLINICAL CANCER RESEARCH
- New adjuvants in evolving vaccine strategies
- (2011) Franco M Buonaguro et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- A clinical trial to evaluate the safety and immunogenicity of the LEISH-F1+MPL-SE vaccine for use in the prevention of visceral leishmaniasis
- (2011) Jaya Chakravarty et al. VACCINE
- Use of defined TLR ligands as adjuvants within human vaccines
- (2010) Malcolm S. Duthie et al. IMMUNOLOGICAL REVIEWS
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors
- (2010) Taro Kawai et al. NATURE IMMUNOLOGY
- Activation of Toll-like receptor 2 by a novel preparation of cell wall skeleton from Mycobacterium bovis BCG Tokyo (SMP-105) sufficiently enhances immune responses against tumors
- (2008) Masashi Murata CANCER SCIENCE
- Engagement of Toll-like receptor-2 on cytotoxic T-lymphocytes occurs in vivo and augments antitumor activity
- (2008) Nicole Asprodites et al. FASEB JOURNAL
- Randomized Phase II Trial of a Toll-Like Receptor 9 Agonist Oligodeoxynucleotide, PF-3512676, in Combination With First-Line Taxane Plus Platinum Chemotherapy for Advanced-Stage Non–Small-Cell Lung Cancer
- (2008) Christian Manegold et al. JOURNAL OF CLINICAL ONCOLOGY
- New horizons in adjuvants for vaccine development
- (2008) Steven G. Reed et al. TRENDS IN IMMUNOLOGY
- Engagement of TLR signaling as adjuvant: Towards smarter vaccine and beyond
- (2008) Amit Lahiri et al. VACCINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search